Antibiotice Iasi Ends 9M 2023 with RON463.4M Turnover, Up 28%, RON76M Net Profit, More than Double the 9M 2022 Level

11.15.2023 By Roxana Rosu

Romanian state-owned pharma producer Antibiotice Iasi for the first nine months of 2023 reported RON463.4 million turnover, up 28%, and RON76 million net profit, more than doubled the RON30 million level of the year-earlier period.

To read the full story, please login. Not a member? Subscribe here.

Reveal Romania! Business news & views.
Find out all you need by reading the entire story
To invest in Romania, you need to find out about its opportunities.
To close a strategic partnership with a Romanian company, you need to learn about its market position and whether it is a trustworthy partner
To grow here, you need to be informed

Subscribe now
Only 50 euros/month (VAT not included)
Get access to reports, news and statistics in the main sectors of Romania’s economy. Follow the strategic moves of companies operating in Romania. We will keep you updated on the latest business events.
Contact: E: newsroom@zfenglish.com (newsroom), marketing@zfenglish.com (Marketing & PR), sales@zfenglish.com (subscriptions)
T: 0040-318.256.431 (Newsroom)
0040-318.256.158, 0040-318.256.408 (Subscriptions Department)
0040-318.256.469, 0040-318.256.470 (Advertising Sales Department)
0040-318.256.427, 0040-318.256.129 (Marketing & PR)

LOGIN / Lost password?

 
Keywords:
Antibiotice Iasi
, earnings